(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 48.96% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.32%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.93%.
Axsome Therapeutics's revenue in 2026 is $708,236,000.On average, 23 Wall Street analysts forecast AXSM's revenue for 2026 to be $50,928,701,215, with the lowest AXSM revenue forecast at $43,753,151,444, and the highest AXSM revenue forecast at $55,936,765,642. On average, 23 Wall Street analysts forecast AXSM's revenue for 2027 to be $82,078,326,770, with the lowest AXSM revenue forecast at $58,509,753,942, and the highest AXSM revenue forecast at $108,631,566,026.
In 2028, AXSM is forecast to generate $122,114,024,718 in revenue, with the lowest revenue forecast at $85,526,131,092 and the highest revenue forecast at $190,246,754,902.